ERBB2 and breast cancer: One of the greatest challenges for BC therapy is the occurrence of intra-tumor cellular heterogeneity [115-118], which negatively affects the efficacy of different approaches to cancer treatment including biological agents such as the anti-HER2 monoclonal antibody trastuzumab (Herceptin).